ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Clinical and radiological factors affecting progression in sarcoidosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTo determine the clinical and radiological indicators of disease progression in a newly diagnosed sarcoidosis patient.
methodsThe data of patients who were diagnosed with sarcoidosis in our department between January 2014 and June 2022 were analyzed. The patients were divided into two groups: progression and non-progression. Groups were compared according to symptoms at the time of diagnosis, comorbidities, foci of extrapulmonary involvement, shape, size, density, and localization of mediastinal lymph nodes, parenchymal findings, disease stage and whether or not treatment was received at the beginning.
resultsThe study included 292 sarcoidosis patients. The number of patients who progressed was 46 (15.8%). It was observed that stage II patients progressed more than stage I patients (p<0,001). The mean time to progression was 38.05±30.45 months in stage I and 28±58 months in stage II patients. Progression rate was higher in patients with right upper paratracheal, subaortic-paraaortic, subcarinal LAP (p= 0.010, p= 0.012, p= 0.020, respectively). The higher number of stations with LAP was associated with the presence of progression (p=0.017). The presence of parenchymal nodules (29/64.4%) and the number of lobes with nodules was also associated with progression (p= 0.027, 0.022, respectively). Progression rate was 76.1% in patients with treatment indication at the time of diagnosis (p<0.001).
conclusionsDisease stage is a prognostically important factor in the course of sarcoidosis, which is supported by our study results. Accordingly, it is important to follow patients with high-stage sarcoidosis more closely and to identify patients with treatment indications in time.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.